Influenza Neuraminidase Characteristics and Potential as a Vaccine Target

Neuraminidase of influenza A and B viruses plays a critical role in the virus life cycle and is an important target of the host immune system. Here, we highlight the current understanding of influenza neuraminidase structure, function, antigenicity, immunogenicity, and immune protective potential. N...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarah Creytens, Mirte N. Pascha, Marlies Ballegeer, Xavier Saelens, Cornelis A. M. de Haan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	influenza neuraminidase antigenic drift monoclonal antibodies correlate of protection vaccines Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/5b8625be21af4b1bbc0ead13de31527f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5b8625be21af4b1bbc0ead13de31527f
record_format	dspace
spelling	oai:doaj.org-article:5b8625be21af4b1bbc0ead13de31527f2021-11-16T06:14:33ZInfluenza Neuraminidase Characteristics and Potential as a Vaccine Target1664-322410.3389/fimmu.2021.786617https://doaj.org/article/5b8625be21af4b1bbc0ead13de31527f2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.786617/fullhttps://doaj.org/toc/1664-3224Neuraminidase of influenza A and B viruses plays a critical role in the virus life cycle and is an important target of the host immune system. Here, we highlight the current understanding of influenza neuraminidase structure, function, antigenicity, immunogenicity, and immune protective potential. Neuraminidase inhibiting antibodies have been recognized as correlates of protection against disease caused by natural or experimental influenza A virus infection in humans. In the past years, we have witnessed an increasing interest in the use of influenza neuraminidase to improve the protective potential of currently used influenza vaccines. A number of well-characterized influenza neuraminidase-specific monoclonal antibodies have been described recently, most of which can protect in experimental challenge models by inhibiting the neuraminidase activity or by Fc receptor-dependent mechanisms. The relative instability of the neuraminidase poses a challenge for protein-based antigen design. We critically review the different solutions that have been proposed to solve this problem, ranging from the inclusion of stabilizing heterologous tetramerizing zippers to the introduction of inter-protomer stabilizing mutations. Computationally engineered neuraminidase antigens have been generated that offer broad, within subtype protection in animal challenge models. We also provide an overview of modern vaccine technology platforms that are compatible with the induction of robust neuraminidase-specific immune responses. In the near future, we will likely see the implementation of influenza vaccines that confront the influenza virus with a double punch: targeting both the hemagglutinin and the neuraminidase.Sarah CreytensSarah CreytensMirte N. PaschaMarlies BallegeerMarlies BallegeerXavier SaelensXavier SaelensCornelis A. M. de HaanFrontiers Media S.A.articleinfluenzaneuraminidaseantigenic driftmonoclonal antibodiescorrelate of protectionvaccinesImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	influenza neuraminidase antigenic drift monoclonal antibodies correlate of protection vaccines Immunologic diseases. Allergy RC581-607
spellingShingle	influenza neuraminidase antigenic drift monoclonal antibodies correlate of protection vaccines Immunologic diseases. Allergy RC581-607 Sarah Creytens Sarah Creytens Mirte N. Pascha Marlies Ballegeer Marlies Ballegeer Xavier Saelens Xavier Saelens Cornelis A. M. de Haan Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
description	Neuraminidase of influenza A and B viruses plays a critical role in the virus life cycle and is an important target of the host immune system. Here, we highlight the current understanding of influenza neuraminidase structure, function, antigenicity, immunogenicity, and immune protective potential. Neuraminidase inhibiting antibodies have been recognized as correlates of protection against disease caused by natural or experimental influenza A virus infection in humans. In the past years, we have witnessed an increasing interest in the use of influenza neuraminidase to improve the protective potential of currently used influenza vaccines. A number of well-characterized influenza neuraminidase-specific monoclonal antibodies have been described recently, most of which can protect in experimental challenge models by inhibiting the neuraminidase activity or by Fc receptor-dependent mechanisms. The relative instability of the neuraminidase poses a challenge for protein-based antigen design. We critically review the different solutions that have been proposed to solve this problem, ranging from the inclusion of stabilizing heterologous tetramerizing zippers to the introduction of inter-protomer stabilizing mutations. Computationally engineered neuraminidase antigens have been generated that offer broad, within subtype protection in animal challenge models. We also provide an overview of modern vaccine technology platforms that are compatible with the induction of robust neuraminidase-specific immune responses. In the near future, we will likely see the implementation of influenza vaccines that confront the influenza virus with a double punch: targeting both the hemagglutinin and the neuraminidase.
format	article
author	Sarah Creytens Sarah Creytens Mirte N. Pascha Marlies Ballegeer Marlies Ballegeer Xavier Saelens Xavier Saelens Cornelis A. M. de Haan
author_facet	Sarah Creytens Sarah Creytens Mirte N. Pascha Marlies Ballegeer Marlies Ballegeer Xavier Saelens Xavier Saelens Cornelis A. M. de Haan
author_sort	Sarah Creytens
title	Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
title_short	Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
title_full	Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
title_fullStr	Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
title_full_unstemmed	Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
title_sort	influenza neuraminidase characteristics and potential as a vaccine target
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/5b8625be21af4b1bbc0ead13de31527f
work_keys_str_mv	AT sarahcreytens influenzaneuraminidasecharacteristicsandpotentialasavaccinetarget AT sarahcreytens influenzaneuraminidasecharacteristicsandpotentialasavaccinetarget AT mirtenpascha influenzaneuraminidasecharacteristicsandpotentialasavaccinetarget AT marliesballegeer influenzaneuraminidasecharacteristicsandpotentialasavaccinetarget AT marliesballegeer influenzaneuraminidasecharacteristicsandpotentialasavaccinetarget AT xaviersaelens influenzaneuraminidasecharacteristicsandpotentialasavaccinetarget AT xaviersaelens influenzaneuraminidasecharacteristicsandpotentialasavaccinetarget AT cornelisamdehaan influenzaneuraminidasecharacteristicsandpotentialasavaccinetarget
_version_	1718426667235409920

Influenza Neuraminidase Characteristics and Potential as a Vaccine Target

Ejemplares similares